Status:
COMPLETED
Safety and Efficacy of Kaletra in ARV Therapy Experienced Patients
Lead Sponsor:
AbbVie (prior sponsor, Abbott)
Conditions:
Human Immunodeficiency Virus
Eligibility:
All Genders
17+ years
Phase:
PHASE4
Brief Summary
To demonstrate that patients treated with Kaletra have an improvement in their quality of life compared to the quality of life they had with their previous NRTI therapy.
Eligibility Criteria
Inclusion
- HIV Infected subjects
- Subjects failing in current HIV treatment, or
- Subjects with a viral load \< 400 copies/mL and not tolerating their current HIV treatment.
Exclusion
- Subject is currently participating in another clinical study or has participated in another clinical study within 30 days prior to screening visit
- Subject is pregnant
Key Trial Info
Start Date :
November 1 2003
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2006
Estimated Enrollment :
207 Patients enrolled
Trial Details
Trial ID
NCT00648999
Start Date
November 1 2003
End Date
December 1 2006
Last Update
March 15 2013
Active Locations (13)
Enter a location and click search to find clinical trials sorted by distance.
1
Site Ref # / Investigator 4074
León, Guanajauto, Mexico
2
Site Ref # / Investigator 4049
Mexico City, Mexico City, Mexico, 01030
3
Site Ref # / Investigator 4050
Mexico City, Mexico City, Mexico, 01120
4
Site Ref # / Investigator 4051
Mexico City, Mexico City, Mexico, 09220